| Sitagliptin Phosphate and Metformin Hydrochloride | Merck | ||
| 500mg/50mg,1gm/50mg,100mg/1gm;Tablet ER |
Less Than $1000 mn
|
||
|
Less Than 5
|
More Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
| None | None | ||
| Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate. | |||
|
Yes
| |||
| Janumet XR | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 |
|---|---|---|---|---|---|---|
| ****** | ******* | ******* | ******* | ******* | ******* | ******* |
| **** | *** ********* | *** ********* | *** ********* | *** ********* | ******* | *** ********* |
| *** ****** | *** ********* | *** ********* | *** ********* | *** ********* | ******* | *** ********* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ****** | ***\ ********* | *** ********** | ******* | ********* ******** | ** *** **** |
| **** | ** \ ** | *** ********** | ******* | ********* ******** | ** *** **** |
| *** ****** | ** \ ** | *** ********** | ******* | **** | ** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|